Repare Therapeutics Names Forte as President, CEO

Like
Comment
Favorite

Repare Therapeutics Names Forte as President, CEO

Dow Jones03-31

By Stephen Nakrosis

Repare Therapeutics on Monday said its Chief Financial Officer, Steve Forte, has been named as the company's president and chief executive officer, effective April 11.

He succeeds Lloyd Segal, who has resigned as president, CEO, and from the board to pursue other opportunities, Repare said.

Forte, who will continue to serve as CFO, will also join Repare's board.

Forte joined Repare Therapeutics in 2019 as executive vice president and CFO. Before that, he was CFO for Clementia Pharmaceuticals, during which Clementia was acquired by Ipsen for $1.3 billion, Repare said.

In after-hours trading, shares of the oncology company were up 4.5%, to $1.03. The stock has lost 79% over the last year.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

March 31, 2025 17:06 ET (21:06 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2524970711?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-04-01 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524970711","market":"hk","top_or_hot":-1,"title":"Repare Therapeutics Names Forte as President, CEO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Repare <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> on Monday said its Chief Financial Officer, Steve Forte, has been named as the company's president and chief executive officer, effective April 11. \n</p>\n<p>\n  He succeeds Lloyd Segal, who has resigned as president, CEO, and from the board to pursue other opportunities, Repare said. \n</p>\n<p>\n  Forte, who will continue to serve as CFO, will also join Repare's board. \n</p>\n<p>\n  Forte joined Repare Therapeutics in 2019 as executive vice president and CFO. Before that, he was CFO for Clementia Pharmaceuticals, during which Clementia was acquired by Ipsen for $1.3 billion, Repare said. \n</p>\n<p>\n  In after-hours trading, shares of the oncology company were up 4.5%, to $1.03. The stock has lost 79% over the last year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 31, 2025 17:06 ET (21:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Repare Therapeutics Names Forte as President, CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRepare Therapeutics Names Forte as President, CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-01 05:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Repare <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> on Monday said its Chief Financial Officer, Steve Forte, has been named as the company's president and chief executive officer, effective April 11. \n</p>\n<p>\n  He succeeds Lloyd Segal, who has resigned as president, CEO, and from the board to pursue other opportunities, Repare said. \n</p>\n<p>\n  Forte, who will continue to serve as CFO, will also join Repare's board. \n</p>\n<p>\n  Forte joined Repare Therapeutics in 2019 as executive vice president and CFO. Before that, he was CFO for Clementia Pharmaceuticals, during which Clementia was acquired by Ipsen for $1.3 billion, Repare said. \n</p>\n<p>\n  In after-hours trading, shares of the oncology company were up 4.5%, to $1.03. The stock has lost 79% over the last year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 31, 2025 17:06 ET (21:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524970711","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524970711","pubTimestamp":1743455160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Repare Therapeutics on Monday said its Chief Financial Officer, Steve Forte, has been named as the company's president and chief executive officer, effective April 11.He succeeds Lloyd Segal, who has resigned as president, CEO, and from the board to pursue other opportunities, Repare said.Forte, who will continue to serve as CFO, will also join Repare's board.Forte joined Repare Therapeutics in 2019 as executive vice president and CFO. Before that, he was CFO for Clementia Pharmaceuticals, during which Clementia was acquired by Ipsen for $1.3 billion, Repare said.In after-hours trading, shares of the oncology company were up 4.5%, to $1.03. The stock has lost 79% over the last year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","RPTX":"Repare Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Repare Therapeutics任命Forte为总裁兼首席执行官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"RPTX":1},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Repare Therapeutics on Monday said its Chief Financial Officer, Steve Forte, has been named as the company's president and chief executive officer, effective April 11. \n\n\n  He succeeds Lloyd Segal, who has resigned as president, CEO, and from the board to pursue other opportunities, Repare said. \n\n\n  Forte, who will continue to serve as CFO, will also join Repare's board. \n\n\n  Forte joined Repare Therapeutics in 2019 as executive vice president and CFO. Before that, he was CFO for Clementia Pharmaceuticals, during which Clementia was acquired by Ipsen for $1.3 billion, Repare said. \n\n\n  In after-hours trading, shares of the oncology company were up 4.5%, to $1.03. The stock has lost 79% over the last year. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 17:06 ET (21:06 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}